Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:50909
Name extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Definition A marginal zone B-cell lymphoma that has_material_basis_in mucosal tissue involved in antibody production.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma marginal zone lymphoma extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02564744 Phase II Naratuximab emtansine + Rituximab Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL Completed USA | POL | ITA | HUN | CZE | CHE | BGR | BEL 1
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT03322865 Phase II Obinutuzumab Obinutuzumab in Marginal Zone Lymphoma Active, not recruiting DEU 0
NCT03474744 Phase II Copanlisib + Rituximab Copanlisib and Rituximab in Marginal Zone Lymphoma Patients Active, not recruiting DEU | AUT 0
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting USA 0
NCT03697512 Phase II Ibrutinib + Rituximab MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU) Active, not recruiting ITA | FRA | CHE | BEL 1
NCT04268277 Phase II Pembrolizumab + Rituximab Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY Recruiting DEU | AUT 0
NCT04578600 Phase I Azacitidine + Lenalidomide + Obinutuzumab CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Active, not recruiting USA 0
NCT04799275 Phase II Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Recruiting USA 0
NCT04824092 Phase III Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND) Active, not recruiting USA | TUR | SVK | ROU | POL | NZL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT | AUS | ARG 10
NCT05003141 Phase I PSB202 PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Unknown status USA | AUS 1
NCT05424822 Phase I JNJ-80948543 A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | POL | ISR | FRA | DNK | AUS 2
NCT06006117 Phase III Lenalidomide + Rituximab Lenalidomide + Mosunetuzumab-axgb Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma Recruiting FRA 0
NCT06300528 Phase II Pemigatinib Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma Not yet recruiting USA 0
NCT06378190 Phase Ib/II TranspoCART19 Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) Recruiting ESP 0
NCT06569680 Phase II Mosunetuzumab-axgb Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma Not yet recruiting USA 0